US Kratom Industry Chafes At FDA’s Short Leash On Science Showing Botanical’s Safety, Benefits

American Kratom Association didn’t convince court to order FDA to extend to deadline for comments responding to World Health Organization’s question on whether kratom should be deemed controlled substances under UN schedule. Short comment period is “latest in what we think is a very hostile action” by FDA about kratom, says AKA executive Mac Haddow.

• Source: Alamy

The US kratom industry sees the short period the Food and Drug Administration allowed for comments on whether kratom should be added to the United Nations’ schedule of controlled substances as another example of the agency’s refusal to consider the botanical’s safety and benefits.

The American Kratom Association didn’t convince a federal judge on 9 August to order the FDA to extend from that...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Regulation

More from Policy & Regulation